CytoDyn Inc. (CYDY)
USD 0.23
(-1.61%)
USD 0.23
(-1.61%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 | -29 Thousand USD | 83.43% |
| 2023 | -175 Thousand USD | -182.16% |
| 2022 | 213 Thousand USD | 111.85% |
| 2021 | -1.79 Million USD | 11.67% |
| 2020 | -2.03 Million USD | -63.39% |
| 2019 | -1.24 Million USD | -249.64% |
| 2018 | -356.12 Thousand USD | 2.8% |
| 2017 | -366.38 Thousand USD | -1.32% |
| 2016 | -361.61 Thousand USD | 0.0% |
| 2015 | - USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 100.0% |
| 2012 | -25.98 Thousand USD | -549.14% |
| 2011 | 5786.00 USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -8000.00 USD | 20.0% |
| 2024 FY | -29 Thousand USD | 83.43% |
| 2024 Q4 | 46 Thousand USD | 757.14% |
| 2024 Q1 | -10 Thousand USD | 0.0% |
| 2024 Q3 | -7000.00 USD | 12.5% |
| 2023 Q1 | -99 Thousand USD | 99.85% |
| 2023 FY | -175 Thousand USD | -182.16% |
| 2023 Q3 | -12 Thousand USD | 99.93% |
| 2023 Q4 | -10 Thousand USD | 16.67% |
| 2023 Q2 | -17.92 Million USD | -18010.1% |
| 2022 Q1 | 40 Thousand USD | 114.55% |
| 2022 FY | 213 Thousand USD | 111.85% |
| 2022 Q4 | -64.57 Million USD | -49957.36% |
| 2022 Q3 | -129 Thousand USD | -174.57% |
| 2022 Q2 | 173 Thousand USD | 332.5% |
| 2021 Q4 | -275 Thousand USD | 0.0% |
| 2021 Q1 | - USD | 0.0% |
| 2021 Q2 | - USD | 0.0% |
| 2021 FY | -1.79 Million USD | 11.67% |
| 2021 Q3 | - USD | 0.0% |
| 2020 Q1 | - USD | 0.0% |
| 2020 Q3 | - USD | 0.0% |
| 2020 FY | -2.03 Million USD | -63.39% |
| 2020 Q4 | - USD | 0.0% |
| 2020 Q2 | - USD | 0.0% |
| 2019 Q2 | - USD | 0.0% |
| 2019 Q1 | - USD | 0.0% |
| 2019 Q3 | - USD | 0.0% |
| 2019 Q4 | - USD | 0.0% |
| 2019 FY | -1.24 Million USD | -249.64% |
| 2018 Q2 | - USD | 0.0% |
| 2018 FY | -356.12 Thousand USD | 2.8% |
| 2018 Q1 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 Q4 | - USD | 0.0% |
| 2017 FY | -366.38 Thousand USD | -1.32% |
| 2017 Q2 | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2016 FY | -361.61 Thousand USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 FY | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 FY | - USD | 100.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2013 Q1 | - USD | -100.0% |
| 2012 Q1 | -23.81 Thousand USD | -511.6% |
| 2012 FY | -25.98 Thousand USD | -549.14% |
| 2012 Q4 | 23.81 Thousand USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2012 Q2 | - USD | 100.0% |
| 2011 FY | 5786.00 USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 Q4 | 5786.00 USD | 0.0% |
| 2011 Q1 | - USD | -100.0% |
| 2010 Q4 | 5786.00 USD | 0.0% |
| 2010 Q1 | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2007 Q1 | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2003 Q1 | - USD | 0.0% |
| 2003 Q2 | - USD | 0.0% |
| 2003 Q3 | - USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Arch Therapeutics, Inc. | -2439.00 USD | -1089.012% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 100.248% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 90.924% |
| Rebus Holdings, Inc. | - USD | Infinity% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 100.024% |
| Qrons Inc. | - USD | Infinity% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 99.888% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 39.908% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 76.66% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 100.193% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | 1034.881% |
| Institute of Biomedical Research Corp. | - USD | Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | 100.296% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | 144.121% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 15.081% |
| Mesoblast Limited | -35.16 Million USD | 99.918% |
| Marizyme, Inc. | 457.7 Thousand USD | 106.336% |
| Genus plc | 178.7 Million USD | 100.016% |
| VioQuest Pharmaceuticals, Inc. | - USD | Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 100.013% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | 146.604% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | 107.07% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | -163.636% |
| ContraFect Corporation | -154 Thousand USD | 81.169% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 42.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | 137.78% |
| IMV Inc. | -962.29 Thousand USD | 96.986% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 92.516% |
| MultiCell Technologies, Inc. | 49.32 USD | 58899.676% |
| ONE Bio Corp. | 20.12 Million USD | 100.144% |
| Accustem Sciences Inc. | - USD | Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 100.072% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | 159.305% |
| Q BioMed Inc. | -8988.00 USD | -222.652% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 100.103% |
| Mosaic ImmunoEngineering Inc. | - USD | Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | -88.019% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 100.065% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 97.46% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | 141.429% |
| GlobeStar Therapeutics Corporation | - USD | Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | -485.622% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | 120.641% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 70.261% |
| GB Sciences, Inc. | -624.00 USD | -4547.436% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 66.29% |
| HST Global, Inc. | - USD | Infinity% |
| CSL Limited | 7.56 Billion USD | 100.0% |
| Wesana Health Holdings Inc. | - USD | Infinity% |
| Halberd Corporation | -208.00 USD | -13842.308% |
| Enzolytics Inc. | 30.7 Thousand USD | 194.438% |
| Agentix Corp. | - USD | Infinity% |
| Resverlogix Corp. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | 106.011% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | 1.1 Billion USD | 100.003% |
| Enzon Pharmaceuticals, Inc. | - USD | Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 94.364% |
| RespireRx Pharmaceuticals Inc. | - USD | Infinity% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | 104.697% |
| Zenith Capital Corp. | - USD | Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 100.007% |
| Ember Therapeutics, Inc. | - USD | Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | -227.462% |
| WPD Pharmaceuticals Inc. | - USD | Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 65.414% |
| Kadimastem Ltd | -630.13 Thousand USD | 95.398% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | 102.935% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 100.302% |
| BioStem Technologies, Inc. | 15.42 Million USD | 100.188% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | - USD | Infinity% |
| LadRx Corporation | -11.83 Thousand USD | -145.036% |
| Cell Source, Inc. | - USD | Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 116.425% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 116.425% |
| NovAccess Global Inc. | - USD | Infinity% |
| Affymax, Inc. | 1.35 Million USD | 102.137% |
| Itoco Inc. | - USD | Infinity% |
| Rasna Therapeutics, Inc. | - USD | Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | Infinity% |
| Mobile Lads Corp. | - USD | Infinity% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | - USD | Infinity% |
| NanoSphere Health Sciences Inc. | - USD | Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | 106.444% |
| SYBLEU INC | 11.69 Thousand USD | 347.948% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 100.629% |
| Bioxytran, Inc. | -8285.00 USD | -250.03% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | - USD | Infinity% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | - USD | Infinity% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | - USD | Infinity% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | - USD | Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 92.225% |
| Neutra Corp. | 14.33 Thousand USD | 302.302% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 64.634% |
| PureTech Health plc | -1.6 Million USD | 98.191% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 97.104% |
| IXICO plc | 3.27 Million USD | 100.887% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 95.821% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 98.381% |
| CSL Limited | 7.7 Billion USD | 100.0% |
| Cellectis S.A. | 18 Thousand USD | 261.111% |